everolimus + bevacizumab

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Malignant Peripheral Nerve Sheath Tumors

Conditions

Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma

Trial Timeline

Sep 1, 2012 → Dec 1, 2017

NCT ID

NCT01661283

About everolimus + bevacizumab

everolimus + bevacizumab is a phase 2 stage product being developed by Novartis for Malignant Peripheral Nerve Sheath Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT01661283. Target conditions include Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01661283	Phase 2	Completed	Sep 1, 2012	Dec 1, 2017	Malignant Peripheral Nerve Sheath Tumors
NCT00972335	Phase 2	Terminated	Jan 1, 2010	Jul 1, 2014	Intracranial Meningioma
NCT00651482	Phase 2	Terminated	Aug 1, 2008	Mar 1, 2012	Kidney Neoplasms

Competing Products

20 competing products in Malignant Peripheral Nerve Sheath Tumors

See all competitors

Product	Company	Stage	Hype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + Bevacizumab	CSPC Pharmaceutical Group Limited	Phase 1/2	40
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	52
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	33
Patritumab Deruxtecan	Daiichi Sankyo	Phase 1/2	41
Tivantinib + FOLFOX	Daiichi Sankyo	Phase 1/2	41
DS-1123	Daiichi Sankyo	Phase 1	33
DS-8201a	Daiichi Sankyo	Phase 1	33
DS-5573a	Daiichi Sankyo	Phase 1	33
DS-6051b	Daiichi Sankyo	Phase 1	33
U3-1565	Daiichi Sankyo	Phase 1	33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue Medications	Daiichi Sankyo	Phase 1/2	41
DS-3201b + DS-3201b	Daiichi Sankyo	Phase 1	33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kg	Daiichi Sankyo	Phase 1	33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	41
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	52
CP-461	Astellas Pharma	Phase 2	52
enfortumab vedotin	Astellas Pharma	Phase 1	33
LNF1901 Monoclonal Antibody Injection	Sun Pharmaceutical	Phase 1	33
Perampanel + Standard of Care	Eisai	Phase 1/2	41
Pembrolizumab + Lenvatinib + Placebo for lenvatinib	Eisai	Phase 3	77

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved